Benjamin M Craig1, Daniel S Tseng. 1. Department of Population Health Sciences, University of Wisconsin, Madison, Wisconsin, USA. bmcraig@wisc.edu
Abstract
PURPOSE: To estimate the cost-effectiveness of gastric bypass in the treatment of severe obesity. SUBJECTS AND METHODS: We performed a cost-effectiveness analysis of gastric bypass versus no treatment from the payer perspective. We discounted quality-adjusted life-years (QALYs), life-years, and cost during the patient's lifetime. Our target group comprised women and men aged 35 to 55 years with a body mass index between 40 and 50 kg/m(2), and who did not have cardiovascular disease and in whom conservative bariatric therapies had been unsuccessful. RESULTS: The base case cost-effectiveness ratios ranged from 5000 dollars to 16,100 dollars per QALY for women and from 10,000 dollars to 35,600 dollars per QALY for men, depending on age and initial body mass index. In a few subgroups of older, less obese men, variation in parameters such as loss of excess weight, obesity-related quality of life, complication rates, and perioperative mortality affected the cost-effectiveness ratios. Parameter variation did not result in meaningful changes in the remaining patients. CONCLUSION: Gastric bypass is a cost-effective alternative to no treatment, providing substantial lifetime benefits in patients who are severely obese.
PURPOSE: To estimate the cost-effectiveness of gastric bypass in the treatment of severe obesity. SUBJECTS AND METHODS: We performed a cost-effectiveness analysis of gastric bypass versus no treatment from the payer perspective. We discounted quality-adjusted life-years (QALYs), life-years, and cost during the patient's lifetime. Our target group comprised women and men aged 35 to 55 years with a body mass index between 40 and 50 kg/m(2), and who did not have cardiovascular disease and in whom conservative bariatric therapies had been unsuccessful. RESULTS: The base case cost-effectiveness ratios ranged from 5000 dollars to 16,100 dollars per QALY for women and from 10,000 dollars to 35,600 dollars per QALY for men, depending on age and initial body mass index. In a few subgroups of older, less obesemen, variation in parameters such as loss of excess weight, obesity-related quality of life, complication rates, and perioperative mortality affected the cost-effectiveness ratios. Parameter variation did not result in meaningful changes in the remaining patients. CONCLUSION: Gastric bypass is a cost-effective alternative to no treatment, providing substantial lifetime benefits in patients who are severely obese.
Authors: S P Sussenbach; A V Padoin; E N Silva; D Benzano; M A Pufal; A S Barhouch; R Chatkin; R J Ramos; A Balestro; C C Mottin Journal: Obes Surg Date: 2012-02 Impact factor: 4.129
Authors: John Saunders; Garth H Ballantyne; Scott Belsley; Daniel J Stephens; Amit Trivedi; Douglas R Ewing; Vincent A Iannace; Rafael F Capella; Annette Wasileweski; Steven Moran; Hans J Schmidt Journal: Obes Surg Date: 2008-05-02 Impact factor: 4.129
Authors: Amy E Rothberg; Laura N McEwen; Andrew T Kraftson; Gina M Neshewat; Christine E Fowler; Charles F Burant; William H Herman Journal: Qual Life Res Date: 2013-10-16 Impact factor: 4.147
Authors: Bruce C M Wang; Edwin S Wong; Rafael Alfonso-Cristancho; Hao He; David R Flum; David E Arterburn; Louis P Garrison; Sean D Sullivan Journal: Eur J Health Econ Date: 2013-03-24